0
selected
-
1.
A therapeutic platelet transfusion strategy without routine prophylactic tranfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation
Wandt H, Wendelin K, Schaefer-Eckart K, Thalheimer M, Schubert MS, Conradi R,, et al.,
Blood. 2008;112((11):): Abstract No. 286.
-
2.
Infusions of fresh frozen plasma to the patients with a high-risk group for hepatic VOD associated with stem cell transplantation reduce its occurrence
Matsumoto M, Kawa K, Yagi H, Park Y, Takeshima Y, Kosaka Y,, et al.,
Blood. 2006;108((11):): Abstract No. 1502.
-
3.
VWF cleaving protease activity and inhibitors in patients with thrombotic thrombocytopenic purpura (TTP) treated with INTERCEPT FFP vs. conventional FFP: results of a phase III trial
Conlan MGC, Corash L, Lin JS, Mintz PD, Neff AT, Malcolm MR, Hillyer CD, Goodnough LT,, et al.,
Vox Sanguinis. 2005;89((S2):):40. Abstract No. 5P-046.
-
4.
vWF cleaving protease activity and inhibitors in patients with thrombotic thrombocytopenic purpura (TTP) treated with INTERCEPT FFP vs. conventional FFP: results of a phase III trial
Conlan MG, Corash L, Lin J, Mintz PD, Neff AT, MacKenzie M, Hillyer CD, Goodnough LT,, et al.,
Transfusion. 2005;45((s3):):30A.. Abstract No. S92-040G.
-
5.
Treatment of thrombotic thrombocytopenic purpura using solvent detergent treated plasma
Rock G, Anderson D, Benny B, Clark W, Leblond P, Sutton D,, et al.,
Blood. 2005;106((11):): Abstract No. 3989.
-
6.
Transfusion of S-303 treated RBCs to treat acute anemia during or following cardiac surgery: results of a phase III trial
Benjamin RJ, McCullough J, Mintz PD, Snyder EL, Spotnitz WD, Wages D,, et al.,
Blood. 2004;104((11):):112a.. Abstract No. 381.
-
7.
Antibody formation to S-303-treated RBCs in the setting of chronic RBC transfusion
Conlan MG, Stassinopoulos A, Garratty G, Wages D, Corash L, Wood L,, et al.,
Blood. 2004;104((11):):112a-113a.. Abstract No. 382.
-
8.
Transfusion of INTERCEPT platelets vs. reference platelets at doses >/=3.0x1011 results in comparable hemostasis and platelet and RBC transfusion requirements. Results of the SPRINT trial
Murphy S, Snyder E, Cable R, Slichter S, Strauss R, McCullough J,, et al.,
Blood. 2003;102((11, Pt 2):):815a.. Abstract No. 3018.
-
9.
Apheresis platelets treated with the INTERCEPT Blood System for pathogen inactivation provide platelet count increments and hemostasis comparable to conventional platelets
Kluter H, Chapuis B, Cazenave J, Hastka J, Beris P, Dufour P,, et al.,
Vox Sanguinis. 2002;83((Suppl 1):):110a.. Abstract No. 331.
-
10.
INTERCEPT platelets are hemostatically as effective as conventional platelets in the prophylaxis and treatment of bleeding: results of the SPRINT trial
Murphy S, Slichter S, McCullough J, Strauss R, Wood L, Lin J,, et al.,
Vox Sanguinis. 2002;83((Suppl 1):):109. Abstract No. 329.